5 completed, 2 terminated, 1 withdrawn. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
Follow orvepitant: new trials by email Literature Review of orvepitant trials Research Report on orvepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects [14C]-orvepitant - Healthy | Phase 1 | Completed | Nerre Therapeutics Ltd. | 6 | 2020-06-01 | 2020-08-07 |
| A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers Orvepitant, Itraconazole - Pharmacokinetic Study in Healthy Male Volunteers | Phase 1 | Completed | Nerre Therapeutics Ltd. | 16 | 2018-06-08 | 2018-10-11 |
| A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis Orvepitant, Placebo - Pruritus, Atopic Dermatitis | Phase 2 | Withdrawn | Nerre Therapeutics Ltd. | 2018-05-01 | 2018-05-15 | |
| Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder orvepitant, Placebo - Post-Traumatic Stress Disorder | Phase 2 | Completed | GlaxoSmithKline | 132 | 2009-11-02 | 2017-09-01 |
| A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder orvepitant, Placebo - Depressive Disorder | Phase 2 | Terminated | GlaxoSmithKline | 343 | 2009-03-11 | 2017-10-13 |
| A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder orvepitant, placebo - Depressive Disorder, Major | Phase 2 | Terminated | GlaxoSmithKline | 328 | 2009-03-01 | 2017-09-12 |
| Food and Relative Bioavailability Study Orvepitant - Depressive Disorder | Phase 1 | Completed | GlaxoSmithKline | 14 | 2008-08-28 | 2017-07-21 |
| 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296) GW823296 tablet, GW823296 matching placebo, Midazolam - Depressive Disorder | Phase 1 | Completed | GlaxoSmithKline | 36 | 2007-06-12 | 2017-08-04 |
Depression (3) · Depressive Disorder (3) · Depressive Disorder, Major (1) · Dermatitis, Atopic (1) · Pruritus (1) · Stress Disorders, Post-Traumatic (1)
GlaxoSmithKline (5) · Nerre Therapeutics Ltd. (3)
United States (3) · Canada (2) · United Kingdom (2) · Germany (1) · Italy (1)